Kristin has been with Salamandra since 2011, focusing on the authoring and preparation of biopharmaceutics and clinical pharmacology content for all types of regulatory documents, including INDs, NDAs, Meeting Briefing Packages, and others. She is proud to have contributed as a primary author to the preparation of NDA sections for drugs that are now approved and available to the U.S. market. Kristin also provides support and advice to clients on the design, interpretation, and implications of results of in vitro and in vivo clinical pharmacology studies. In addition, Kristin has particular interest in pharmacokinetic and pharmacodynamic modeling and has completed graduate-level coursework in pharmacometrics.
At Salamandra, Kristin enjoys the variety of projects she works on as a consultant and being part of a multidisciplinary team. She is motivated by the desire to be a continual learner and is always looking for ways to become a better technical writer. Kristin looks forward to the opportunity to mentor junior staff in coming years.
What is the story behind the image in your letter?
“In my experience, life is never better than when on a sailboat! Ask me about my past and future sailing adventures.”
17 March 2026
The first-in-human (FIH) and early Phase 1 studies are a pivot point in drug development, where proof of concept pharmacodynamics (PD), safety, and exposure data translate into evidence for regulatory decision making and recommendations for clinical use of a product begin to take shape. Regulators expect a coherent, science-driven plan that links nonclinical safety and absorption, distribution, metabolism, and excretion (ADME) data to a defensible human starting dose and an escalation scheme with appropriate safeguards. As development progresses, a clinical pharmacology package should be capable of informing exposure-response analyses, as well as dosage and administration instructions that facilitate the safe and effective use of a drug (e.g., food effects, use in special populations, and drug-drug interactions [DDIs]). These early human studies are built on a foundation of nonclinical work (refer to our earlier Insight on How a Nonclinical Program Can Help Identify and Mitigate Risks). Early dialogue via a pre-Investigational New Drug Application (pre-IND) meeting helps de-risk assumptions about starting dose, escalation, and safety monitoring, and aligns expectations for the Phase 1 plan.
Figure 1: Early Phase 1 Development Schematic
A systematic understanding of ADME should precede first dosing. The ICH M12 guideline1 outlines expectations for characterizing enzyme- and transporter-mediated DDI liabilities, first using in vitro systems to estimate clinical risk and determine when in vivo studies are warranted. Minimally, studies to identify the enzymes responsible for metabolism of an investigational drug (i.e., reaction phenotyping studies) should be completed before any clinical study is initiated in humans. Other studies may follow later, to be completed before the drug is used in clinical studies enrolling participants with the disease of interest, when DDIs arising from polypharmacy become more relevant and use of concomitant medications can impact eligibility. However, many Sponsors will elect to complete a full panel of in vitro studies of cytochrome P450 (CYP) and transporter-mediated interactions, addressing substrate, inhibition, and induction potential of a drug at the pre-IND stage. This early information on drug disposition informs many safety and operational choices. These choices can include, but are not limited to, whether and when to conduct a radiolabeled mass balance study, development and validation of an assay for an active metabolite, exclusion criteria for concomitant medications in future clinical trials, and the need for renal and hepatic impairment studies. It facilitates strategic and streamlined planning for a DDI program and reduces the likelihood of later-stage surprises.
The primary objective of pharmacokinetic (PK) evaluations in early Phase 1 studies is to generate reliable systemic exposure data (i.e., Cmax and AUC) over a range of doses. Important information established by these studies include PK linearity and the potential for accumulation with repeated dosing. These data form the foundation for safety-margin calculations, determination of DDI cut-off values (as defined by ICH M12), and ultimately the exposure-response relationships that guide dose optimization in later phases. Sponsors should also decide when to assess food effect. For orally administered small molecules, FDA encourages an early evaluation of the impact of food on rate and extent of absorption2. Many programs successfully integrate a crossover food-effect component into single-ascending-dose (SAD) design or run a small add-on cohort once tolerability is established.
Because decisions based in PK data can stand or fall with assay quality, bioanalytical method validation should be planned and completed before the first human participant is dosed. Bioanalytical method validation guidance defined by ICH M103 specifies expectations for accuracy, precision, selectivity, carryover, stability, and incurred sample reanalysis, providing a harmonized global standard. This guidance sets the bar for both method validation and study sample analysis so that PK endpoints can bear regulatory weight and support cross-study comparisons. Designing an appropriate PK sampling schedule is as important as method validation. To estimate half-life with confidence, especially for multiphasic profiles, schedules should include dense early sampling to define absorption/distribution and sufficient late timepoints to capture the terminal slope. Under-sampling the terminal phase in the initial Phase 1 study risks misinterpretations and data gaps that can negatively impact efficiency of the overall clinical pharmacology program and obfuscate predicted accumulation and selection of a dosing interval. A prospectively defined population PK strategy can integrate rich SAD data from the initial Phase 1 study with sparser data collected in the target population later in development, but modeling cannot rescue systematically missing terminal data.
For novel small molecules, planning for how to address assessment of QT/QTc interval prolongation and proarrhythmic potential deserves early consideration given that it can amount to one of the most expensive and resource intensive Phase 1 studies conducted. Most conservatively, this involves the completion of a dedicated thorough QT study4 conducted at doses that produce systemic exposure that is multiples above the exposure at the maximum therapeutic dose; such a study would include concurrent placebo and positive controls. Alternative approaches defined by more recent guidance (E14 and S7B Q&A5) are possible but can involve the integration of in vivo nonclinical and in vitro ion-channel data together with data collected in SAD/MAD studies and the application of concentration-QT modeling. A Sponsor’s ability to leverage these elements as part of a totality of evidence assessment for QT prolongation risk depends upon early planning.
While it is expected, and widely accepted, that early clinical formulations may differ substantially from those used in later-stage clinical or commercial development, early understanding of biopharmaceutics properties and strategic choices made in Phase 1 can reduce the likelihood of needing bridging studies later on. For an oral dosage form, early programs often begin with solutions, suspensions, or simple capsules for pragmatic reasons, but in some cases Chemistry, Manufacturing, and Controls (CMC) programs can support the early introduction of a prototype tablet. Foundational properties such as solubility, permeability, and Biopharmaceutics Classification System (BCS) category can strongly affect dosage form performance. Bridging risk is elevated when a molecule exhibits pH-dependent solubility or permeability constraints, typical of BCS II or IV compounds, given that absorption can be sensitive to physiological variability. By extension, molecules with notable food effects or nonlinear absorption profiles are more likely to show meaningful differences in exposure if drug product composition evolves over time.
Perhaps less obvious than changes to dosage form or composition, changes to manufacturing processes can also have an impact on bioavailability. For example, if the drug substance is crystalline, there may be more than one stable polymorphic form with polymorphs having different solubilities. A change in the polymorphic form(s) of the drug substance can, therefore, influence dosage form performance. This example illustrates that CMC changes should not be made in isolation, but rather with cross-disciplinary input and consideration for impact on bioavailability. Early understanding of this allows teams to optimize the timing of formulation development. For orally administered drugs, it is also essential to recognize that a formal food‑effect assessment must be conducted using the final formulation intended for marketing2. Thus, while Sponsors should test the effect of food on a new drug product before conducting the pivotal safety and efficacy trials to provide rational decisions regarding dosing with respect to food, this assessment may need to be repeated if the formulation changes.
This overview focuses on the initial development considerations for a novel, orally administered small-molecule drug. It is important to acknowledge that expectations can differ for other therapeutic modalities such as biologics, peptides, and oligonucleotides. For these product types, the relevance and design of early clinical pharmacology evaluations may diverge from the approach taken for small molecules based on modality-specific mechanisms, disposition pathways, and safety considerations. Despite these differences, the overarching goals remain consistent: early‑phase studies should establish a foundational understanding of PK and PD, generate pharmacologically relevant exposure data, and collect the evidence needed to inform safe, effective dosing strategies as development moves into the target population.
In aggregate, a well-executed early-phase program should emerge with (i) a defined exposure range that is both safe and pharmacologically relevant; (ii) a robust estimate of half-life and accumulation to support rational dosing frequency; (iii) an initial view of food-effect, DDI, QT prolongation risk, as applicable, anchored in validated in-vitro studies and exposure cutoffs; and (iv) PK datasets and assays suitable for future use in decision making. Model-informed drug development (i.e., population PK, PBPK, and exposure-response analyses) can and should be used to integrate findings and justify next steps in the development process. With thoughtful planning, Sponsors can meet FDA/ICH expectations while compressing timelines through adaptive designs, parallel tasking (e.g., assay validation alongside GLP toxicity studies), and early, well-scoped assessments of fundamental physicochemical, PK, and PD properties.
Salamandra is experienced in navigating regulatory expectations for clinical pharmacology assessments. Our team routinely supports Sponsors through IND preparation and early clinical development, including identifying efficient strategies to reduce timelines and cost over time. To learn how a robust clinical pharmacology strategy can strengthen your program at every stage, reach out to us at hello@salamandra.net.
This article is Part 3 of a series to explore expectations and requirements for early drug development from the nonclinical, clinical pharmacology, clinical, and CMC perspectives.
FDA Guidance for Industry: Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations (June 2022). Accessed at:
https://www.fda.gov/media/121313/download
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (October 2005). Accessed at:
https://www.fda.gov/media/71372/download
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential – Questions and Answers (August 2022). Accessed at:
https://www.fda.gov/media/161198/download